Tislelizumab and chemotherapy for kidney pelvis cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab) and a chemotherapy drug (nab-paclitaxel) to treat kidney pelvis cancer while trying to save as much kidney function as possible. It may be an option if you have a small tumor in the kidney pelvis and are scheduled for a laser procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your tumor is in the kidney pelvis, smaller than 3 cm, and has not spread to lymph nodes or other organs
- You are scheduled to have a laser treatment through a scope (ureteroscopy)
- Your doctor expects you to live at least 12 more weeks
- You can provide blood, urine, and tissue samples for testing
- Your kidney function is good enough, with a total filtration rate of at least 15 ml/min
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
This trial tests a new treatment given before surgery for kidney cancer that is at high risk of coming back. The goal is to see if the treatment shrinks the tumor or improves surgery outcomes.
Hear when a new Renal Pelvic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.